What's Happening

Stay up to date on pharmaceutical developments, industry issues, and what’s happening with Healthesystems

Events

Healthesystems’ conferences and speaking engagements

WCI Annual Conference

August 21-24, 2022 in Orlando Florida

Visit Healthe in booth #913 to learn more about our workers’ comp pharmacy & ancillary benefits

National Comp (NWCD Conference)

October 19-21, 2022 Las Vegas, Nevada

Visit Healthe in booth #621 to participate in our Annual Industry Survey for a chance to win $500

Attend our VP of Clinical Services, Dr. Silvia Sacalis’ session on Thursday 10/20 @ 2pm: “Building an Employee Culture of Well-Being and Trust Amid COVID and Beyond”

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

ZYNRELEF (BUPIVACAINE AND MELOXICAM) EXTENDED-RELEASE SOLUTION

Approval Date: May 2021

Note: New Product

A combination of an amide local anesthetic and an NSAID for postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty

hello world!

LYBALVI (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE

Approval Date: May 2021

Note: New Product

A combination antipsychotic and opioid antagonist for the treatment of schizophrenia, bipolar I disorder

hello world!

KLOXXADO (NALOXONE HYDROCHLORIDE) NASAL SPRAY

Approval Date: Apr 2021

Note: New Product

For the emergency treatment of known or suspected opioid overdose. While other naloxone sprays were previously available in 2 mg and 4 mg doses, this drug has been approved at an 8 mg dose

hello world!

LYRICA® CR (PREGABALIN) EXTENDED-RELEASE TABLETS

Approval Date: Apr 2021

Note: First-Time Generic

For the management of neuropathic pain associated with diabetic neuropathy; post-herpetic neuralgia. While previous generic versions of Lyrica have been approved in the past, this generic approval is for the Extended-Release tablets

hello world!

HYSINGLA® ER (HYDROCODONE BITARTRATE) EXTENDED-RELEASE TABLETS

Approval Date: Mar 2021

Note: First-Time Generic

For the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

hello world!

ZEGALOGUE® (DASIGLUCAGON) INJECTION FOR SUBCUTANEOUS USE

Approval Date: Mar 2021

Note: New Product

For the treatment of severe hypoglycemia in diabetic patients

hello world!

Posimir® (bupivacaine solution) for infiltration use

Approval Date: Feb 2021

Note: new product

Indicated for 72-hour post-surgical analgesia following shoulder surgery

hello world!

Acetaminophen injection

Approval Date: Feb 2021

Note: New Dosage/Formulation

A new 500 mg dose indicated for the management of mild to moderate pain, or moderate to severe pain with adjudicative opioid analgesics

hello world!

Cabenuva (cabotegravir and rilpivirine extended-release injectable suspension)

Approval Date: Jan 2021

Note: New Product

A complete regimen for the treatment of HIV-1 infection to replace current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the first FDA-approved injectable, complete regimen for HIV, administered once a month

hello world!

Norvir® (ritonavir) capsules

Approval Date: Dec 2020

Note: First-Time Generic

Indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection

hello world!

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmenucross-circle